Research advances on the usage of traditional Chinese medicine for neuroprotection in glaucoma

Journal of Chinese Integrative Medicine

Volumn 11, Issue 4, 2013, Pages 233-240

  Mi, Xue Song ^a,b   Zhong, Jing Xiang ^a   Chang, Raymond Chuen Chung ^a,b   So, Kwok Fai ^a,b  

^a JINAN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Glaucoma; Neuroprotection; Neuroprotective agents; Review; Traditional Chinese medicine

Indexed keywords

BETA CRYSTALLIN; BETAINE; BILOBALIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR; FLAVONOID; GINKGO BILOBA EXTRACT; GINKGOLIDE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; LACTONE DERIVATIVE; MEMANTINE; NEUROTROPHIN 3; NEUROTROPHIN 4; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLYSACCHARIDE; SOMATOMEDIN C;

CHINESE MEDICINE; CYTOTOXICITY; DEMENTIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GINKGO BILOBA; GLAUCOMA; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; ISCHEMIA; LYCIUM BARBARUM; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FOLDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; RETINA GANGLION CELL; REVIEW;

EID: 84880972497     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jintegrmed2013037     Document Type: Review

References (70)

1. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? Br J Ophthalmol. 2001; 85(11): 1277-1282.
2. Quigley HA. Glaucoma. Lancet. 2011; 377(9774): 1367-1377.
3. Quigley HA. Clinical trials for glaucoma neuroprotection are not impossible. Curr Opin Ophthalmol. 2012; 23(2): 144-154.
4. McKinnon SJ. Glaucoma: ocular Alzheimer's disease. Front Biosci. 2003; 8: s1140-s1156.
5. Flammer J, Orgül S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP, Stefánsson E. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002; 21(4): 359-393.
6. Vingrys AJ. The many faces of glaucomatous optic neuropathy. Clin Exp Optom. 2000; 83(3): 145-160.
7. Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res. 2012; 31(2): 152-181.
8. Chader GJ. Advances in glaucoma treatment and management: neurotrophic agents. Invest Ophthalmol Vis Sci. 2012; 53(5): 2501-2505.
9. Nakatani M, Shinohara Y, Takii M, Mori H, Asai N, Nishimura S, Furukawa-Hibi Y, Miyamoto Y, Nitta A. Periocular injection of in situ hydrogels containing Leu-Ile, an inducer for neurotrophic factors, promotes retinal ganglion cell survival after optic nerve injury. Exp Eye Res. 2011; 93(6): 873-879.
10. Parrilla-Reverter G, Agudo M, Sobrado-Calvo P, Salinas-Navarro M, Villegas-Pérez MP, Vidal-Sanz M. Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury: a quantitative in vivo study. Exp Eye Res; 2009; 89(1): 32-41.
11. Wen R, Tao W, Li Y, Sieving PA. CNTF and retina. Prog Retin Eye Res. 2012; 31(2): 136-151.
12. Zhou X, Xia XB, Xiong SQ. Neuro-protection of retinal stem cells transplantation combined with copolymer-1 immunization in a rat model of glaucoma. Mol Cell Neurosci. 2013; 54: 1-8.
13. Harper MM, Grozdanic SD, Blits B, Kuehn MH, Zamzow D, Buss JE, Kardon RH, Sakaguchi DS. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. Invest Ophthalmol Vis Sci. 2011; 52(7): 4506-4515.
14. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996; 114(3): 299-305.
15. Giulian D. Reactive glia as rivals in regulating neuronal survival. Glia. 1993; 7(1): 102-110.
16. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996; 37(8): 1618-1624.
17. Siliprandi R, Canella R, Carmignoto G, Schiavo N, Zanellato A, Zanoni R, Vantini G. N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina. Vis Neurosci. 1992; 8(6): 567-573.
18. Ahmed FA, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of α2 agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res. 2001; 913(2): 133-139.
19. Sacca S. Nitric oxide as a mediator of glaucoma pathogenesis. Med Sci Monit. 2002; 8(8): LE33-LE34.
20. Aslan M, Cort A, Yucel I. Oxidative and nitrative stress markers in glaucoma. Free Radic Biol Med. 2008; 45(4): 367-376.
21. Siu AW, Leung MC, Ho To C, Siu FK, Ji J, So KF. Total retinal nitric oxide production is increased in intraocular pressure-elevated rats. Exp Eye Res. 2002; 75(4): 401-406.
22. Neufeld AH, Shareef S, Pena J. Cellular localization of neuronal nitric oxide synthase (NOS-1) in the human and rat retina. J Comp Neurol. 2000; 416(2): 269-275.
23. Nucci C, Morrone L, Rombolà L, Nisticò R, Piccirilli S, Cerulli L. Multifaceted roles of nitric oxide in the lateral geniculate nucleus: from visual signal transduction to neuronal apoptosis. Toxicol Lett. 2003; 139(2-3): 163-173.
24. Liu B, Neufeld AH. Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro. Arch Ophthalmol. 2001; 119(2): 240-245.
25. Klein C. Nitric oxide and the other cyclic nucleotide. Cell Signal. 2002; 14(6): 493-498.
26. Groc L, Jackson Hunter T, Jiang H, Bezin L, Koubi D, Corcoran GB, Levine RA. Nitric oxide synthase inhibition during development: effect on apoptotic death of dopamine neurons. Brain Res Dev Brain Res. 2002; 138(2): 147-153.
27. Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF. Neuroprotection in glaucoma-Is there a future role? Exp Eye Res. 2010; 91(5): 554-566.
28. Danesh-Meyer HV. Neuroprotection in glaucoma: recent and future directions. Curr Opin Ophthalmol. 2011; 22(2): 78-86.
29. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006; 2(4): 337-346.
30. Osborne NN. Pathogenesis of ganglion "cell death" in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog Brain Res. 2008; 173: 339-352.
31. Ho YS, So KF, Chang RC. Drug discovery from Chinese medicine against neurodegeneration in Alzheimer's and vascular dementia. Chin Med. 2011; 6: 15.
32. Chang RC, So KF. Use of anti-aging herbal medicine, Lycium barbarum, against aging-associated diseases. What do we know so far? Cel Mol Neurobiol. 2008; 28(5): 643-652.
33. Luo Q, Cai Y, Yan J, Sun M, Corke H. Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum. Life Sci. 2004; 76(2): 137-149.
34. Jin M, Huang Q, Zhao K, Shang P. Biological activities and potential health benefit effects of polysaccharides isolated from Lycium barbarum L. Int J Biol Macromol. 2013; 54: 16-23.
35. Yu MS, Leung SK, Lai SW, Che CM, Zee SY. Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against β-amyloid peptide neurotoxicity. Exp Gerontol. 2005; 40: 716-727.
36. Ho YS, Yu MS, Yik SY, So KF, Yuen WH, Chang RCC. Polysaccharides from wolfberry antagonizes glutamate excitotoxicity in rat cortical neurons. Cell Mol Neurobiol. 2009; 29(8): 1233-1244.
37. Chiu K, Zhou Y, Yeung SC, Lok CK, Chan OO, Chang RC, So KF, Chiu JF. Up-regulation of crystallins is involved in the neuroprotective effect of wolfberry on survival of retinal ganglion cells in rat ocular hypertension model. J Cell Biochem. 2010; 110(2): 311-320.
38. Chan HC, Chang RC, Koon-Ching Ip A, Chiu K, Yuen WH, Zee SY, So KF. Neuroprotective effects of Lycium barbarum Lynn on protecting retinal ganglion cells in an ocular hypertension model of glaucoma. Exp Neurol. 2007; 203(1): 269-273.
39. Li SY, Yeung CM, Yu WY, Chang RC, So KF, Wong D, Lo AC. Lycium barbarum polysaccharides reduce neuronal damage, blood-retinal barrier disruption and oxidative stress in retinal ischemia/reperfusion injury. PLoS One. 2011; 6(1): e16380.
40. Ho YS, So KF, Chang RC. Anti-aging herbal medicine-How and why can they be used in aging-associated neurodegenerative diseases? Ageing Res Rev. 2010; 9(3): 354-362.
41. Chiu K, Chan HC, Yeung SC, Yuen WH, Zee SY, Chang RC, So KF. Modulation of microglia by Wolfberry on the survival of retinal ganglion cells in a rat ocular hypertension model. J Ocul Biol Dis Infor. 2009; 2(3): 127-136.
42. Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr Opin Pharmacol. 2013; 13(1): 23-31.
43. Tezel G, Thornton IL, Tong MG, Luo C, Yang X, Cai J, Powell DW, Soltau JB, Liebmann JM, Ritch R. Immunoproteomic analysis of potential serum biomarker candidates in human glaucoma. Invest Ophthalmol Vis Sci. 2012; 53(13): 8222-8231.
44. Moalem G, Monsonego A, Shani Y, Cohen IR, Schwartz M. Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J. 1999; 13(10): 1207-1217.
45. Barouch R, Schwartz M. Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: implications for protective autoimmunity. FASEB J. 2002; 16(10): 1304-1306.
46. Bosco A, Steele MR, Vetter ML. Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol. 2011; 519(4): 599-620.
47. Gan L, Zhang SH, Liu Q, Xu HB. A polysaccharide-protein complex from Lycium barbarum upregulates cytokine expression in human peripheral blood mononuclear cells. Eur J Pharmacol. 2003; 471(3): 217-222.
48. Yu MS, Ho YS, So KF, Yuen WH, Chang RC. Cytoprotective effects of Lycium barbarum against reducing stress on endoplasmic reticulum. Int J Mol Med. 2006; 17(6): 1157-1161.
49. Krishnamoorthy RR, Rao VR, Dauphin R, Prasanna G, Johnson C, Yorio T. Role of the ETB receptor in retinal ganglion cell death in glaucoma. Can J Physiol Pharmacol. 2008; 86(6): 380-393.
50. Mi XS, Chiu K, Van G, Leung JWC, Lo AC, Chung SK, Chang RC, So KF. Effect of Lycium barbarum polysaccharides on the expression of endothelin-1 and its receptors in an ocular hypertension model of rat glaucoma. Neural Regen Res. 2012; 7(9): 645-651.
51. Mi XS, Feng Q, Lo AC, Chang RC, Lin B, Chung SK, So KF. Protection of retinal ganglion cells and retinal vasculature by Lycium barbarum polysaccharides in a mouse model of acute ocular hypertension. PLoS One. 2012; 7(10): e45469.
52. Chen DF, Cho KS. Optic neuropathy and ganglion cell degeneration in glaucoma: mechanisms and therapeutic strategies. In: Tombran-Tink J, Barnstable CJ, Shields MB. Mechanisms of the glaucomas: disease processes and therapeutic modalities. Totowa: Humana Press. 2008: 393-423.
53. Peng Y, Ma C, Li Y, Leung KS, Jiang ZH, Zhao Z. Quantification of zeaxanthin dipalmitate and total carotenoids in Lycium fruits (Fructus Lycii). Plant Foods Hum Nutr. 2005; 60(4): 161-164.
54. Benzie IF, Chung WY, Wang J, Richelle M, Bucheli P. Enhanced bioavailability of zeaxanthin in a milk-based formulation of wolfberry (Gou Qi Zi; Fructus barbarum L.). Br J Nutr. 2006; 96(1): 154-160.
55. Llansola M, Erceg S, Hernandez-Viadel M, Felipo V. Prevention of ammonia and glutamate neurotoxicity by carnitine: molecular mechanisms. Metab Brain Dis. 2002; 17(4): 389-397.
56. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009; (1): CD003120.
57. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000; 1(1): 25-58.
58. Chung SY, Cheng FC, Lee MS, Lin JY, Lin MC, Wang MF. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain. Am J Chin Med. 2006; 34(5): 803-817.
59. Chung HS, Harris A, Kristinsson JK, Ciulla TA, Kagemann C, Ritch R. Ginkgo biloba extract increases ocular blood flow velocity. J Ocul Pharmacol Ther. 1999; 15(3): 233-240.
60. Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ. Shortterm effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. Korean J Ophthalmol. 2011; 25(5): 323-328.
61. Domoráková I, Mechírová E, Danková M, Danielisová V, Burda J. Effect of antioxidant treatment in global ischemia and ischemic postconditioning in the rat hippocampus. Cell Mol Neurobiol. 2009; 29(6-7): 837-844.
62. Nada SE, Shah ZA. Preconditioning with Ginkgo biloba (EGb 761®) provides neuroprotection through HO1 and CRMP2. Neurobiol Dis. 2012; 46(1): 180-189.
63. Saleem S, Zhuang H, Biswal S, Christen Y, Doré S. Ginkgo biloba extract neuroprotective action is dependent on heme oxygenase 1 in ischemic reperfusion brain injury. Stroke. 2008; 39(12): 3389-3396.
64. Shah ZA, Nada SE, Doré S. Heme oxygenase 1, beneficial role in permanent ischemic stroke and in Gingko biloba (EGb 761) neuroprotection. Neuroscience. 2011; 180: 248-255.
65. Mdzinarishvili A, Sumbria R, Lang D, Klein J. Ginkgo extract EGb761 confers neuroprotection by reduction of glutamate release in ischemic brain. J Pharm Pharm Sci. 2012; 15(1): 94-102.
66. Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol. 2007; 52 (Suppl 2): S162-S173.
67. Koh PO. Gingko biloba extract (EGb 761) prevents increase of Bad-Bcl-XL interaction following cerebral ischemia. Am J Chin Med. 2009; 37(5): 867-876.
68. Smith JV, Burdick AJ, Golik P, Khan I, Wallace D, Luo Y. Anti-apoptotic properties of Ginkgo biloba extract EGb 761 in differentiated PC12 cells. Cell Mol Biol (Noisy-legrand). 2002; 48(6): 699-707.
69. Khoury R, Cross JM, Girkin CA, Owsley C, McGwin G Jr. The association between self-reported glaucoma and Ginkgo biloba use. J Glaucoma. 2009; 18(7): 543-545.
70. Hirooka K, Tokuda M, Miyamoto O, Itano T, Baba T, Shiraga F. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr Eye Res. 2004; 28(3): 153-157.